Health plan type highly influences the likelihood of biosimilar uptake, with low-flexibility insurance plans more likely to have patients who either switched to a biosimilar or were initiated on a biosimilar.
Results revealed the health plan type highly influenced the likelihood of biosimilar uptake, with low-flexibility insurance plans more likely to have patients who either switched to a biosimilar or were initiated on a biosimilar.
More than just Wall Street types or stock market prognosticators, Johns Hopkins economics faculty and students apply their tools to address the world's most important issues